All In MedTech

FDA Clearance Tracker · P130007

ANIMAS VIBE SYSTEM

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Nov 25, 2014 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product code

Decided

Nov 25, 2014

Approval withdrawn

Time to decision

587 days

Received Apr 17, 2013. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P130007
Device name
ANIMAS VIBE SYSTEM
Applicant
Animas Corp.
Applicant location
Wayne, PA
Received
Apr 17, 2013
Decided
Nov 25, 2014
Decision
Approval withdrawn
Supplements
30 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code OYC

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE ANIMAS VIBE SYSTEM. THIS DEVICE IS INDICATED FOR:THE ANIMAS® VIBE¿ SYSTEM CONSISTS OF THE ANIMAS® VIBE¿ INSULIN PUMP PAIRED WITH THE DEXCOM G4 PLATINUM SENSOR AND TRANSMITTER.THE ANIMAS® VIBE¿ INSULIN PUMP IS INDICATED FOR CONTINUOUS SUBCUTANEOUS INSULIN INFUSION FOR THE MANAGEMENT OF INSULIN-REQUIRING DIABETES. IT CAN BE USED SOLELY FOR CONTINUOUS INSULIN DELIVERY AND AS PART OF THE ANIMAS® VIBE¿ SYSTEM TO RECEIVE AND DISPLAY CONTINUOUS GLUCOSE MEASUREMENTS FROM THE DEXCOM G4 PLATINUM SENSOR AND TRANSMITTER.THE ANIMAS® VIBE¿ SYSTEM'S CONTINUOUS GLUCOSE MONITORING (CGM) IS INDICATED FOR DETECTING TRENDS AND TRACKING PATTERNS IN PERSONS (AGE 18 AND OLDER) WITH DIABETES, AND IS INTENDED TO COMPLEMENT, NOT REPLACE, INFORMATION OBTAINED FROM STANDARD HOME GLUCOSE MONITORING DEVICES. CGM AIDS IN THE DETECTION OF EPISODES OF HYPERGLYCEMIA AND HYPOGLYCEMIA, FACILITATING BOTH ACUTE AND LONG-TERM THERAPY ADJUSTMENTS, WHICH MAY MINIMIZE THESE EXCURSIONS. INTERPRETATION OF RESULTS FROM THE DEXCOM G4 PLATINUM SENSOR AND TRANSMITTER SHOULD BE BASED ON THE TRENDS AND PATTERNS SEEN WITH SEVERAL SEQUENTIAL READINGS OVER TIME. THE SYSTEM IS INTENDED FOR SINGLE PATIENT USE AND REQUIRES A PRESCRIPTION.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code OYC (Pump, infusion, insulin, to be used with invasive glucose sensor).
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Animas Corp.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.